Abstract
Objective: This study aims to explore the impact of silent GSTP1 gene on the proliferation activity, cell cycle and apoptotic rate of the androgen-independent prostate cancer cell strain DU145. Methods: Thirty subjects with benign prostatic hyperplasia (BPH) who had been subject to urinary surgical resection and pathological diagnosis, 30 subjects with radically cured prostate cancer (PCa), and another 30 subjects with hormone refractory prostate cancer (HRPC) were enrolled. The GSTP1 expression in the subjects was tested with the immunohistochemical S-P method, the GSTP1 expression in the blood serum of the patients with prostatic hyperplasia and prostate cancer was tested with Elisa, and the mRNA level of the GSTP1 gene after the DUl45 cells were transfected with shRNA was tested. Results: Four of the HRPC patients were complicated with bone metastasis, two with bladder invasion, and five with liver and lung metastasis. GSTP1 showed high expression in tissues with prostatic hyperplasia and hormone refractory prostate cancer and low expression in tissues with prostate cancer, and the differences were statistically significant (P 0.05). The GSTP1 mRNA content decreased significantly after shRNA554 intervention, with an IOD value of 67.1±8.7. The intervention effect was evidently lower than that of the carrier shRNA255 group (162.2±12.6) and the shRNA593 group (114.5±10.6) with statistically significant difference (P<0.01). Conclusion: The expression vector-mediated GSTP1-shRNA554 transfection can reduce the mRNA level of the GSTP1 gene of the androgen-independent prostate cancer DU145 cells and inhibit the proliferation activity of the in vitro cultivated DU145 cells.
Highlights
As the most common malignancy in the United States and Europe, prostate cancer (PCa) is showing the second greatest morbidity and mortality in the males of Western countries
Two thirds of the prostate cancer patients can only be treated with endocrine therapy featuring maximal androgen blockade (MAB) once the diagnosis shows that they have missed the opportunity for radical cure [2]
30 subjects with benign prostatic hyperplasia (BPH) who had been subject to urinary surgical resection and pathological diagnosis, 30 subjects with radically cured prostate cancer (PCa), and another 30 subjects with hormone refractory prostate cancer (HRPC) were enrolled
Summary
As the most common malignancy in the United States and Europe, prostate cancer (PCa) is showing the second greatest morbidity and mortality in the males of Western countries. There are annually 28,900 people dying of HRPC in the United States. With the improvement of living standards and average life expectancy, prostate cancer is having an increasing morbidity in China, ranking the third among the malignant tumors of the male urinary and reproductive system [1]. The prostate cancers that recur and progress after continued endocrine therapy include androgen-independent prostate cancer (AIPC) and hormone-refractory prostate cancer (HRPC). Two thirds of the prostate cancer patients can only be treated with endocrine therapy featuring maximal androgen blockade (MAB) once the diagnosis shows that they have missed the opportunity for radical cure [2]. After 12 to 18 months, 70% to 80% of the patients would turn to be Ruirui Xu et al.: Effects of shRNA Expression Vector-mediated Glutathione S-transferase P1 Gene
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: American Journal of Clinical and Experimental Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
